First human test of new drug for tough blood cancers halted early
Disease control
Terminated
This early-stage study tested a new drug called NC525 in adults with advanced blood cancers that had returned or stopped responding to standard treatments. The main goal was to check the drug's safety and side effects in 28 participants. The study was terminated early, and while …
Phase: PHASE1 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Mar 02, 2026 15:26 UTC